Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 171
Filtrar
1.
Scand J Med Sci Sports ; 28 Suppl 1: 61-73, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30001572

RESUMEN

This study investigated the association between long-term adherence to football training and retaining bone mineralization and physical capacity in men with prostate cancer (PCa) managed with androgen deprivation therapy (ADT). Patients completing follow-up at 32 weeks in the FC Prostate Randomized Controlled Trial (RCT) in 2012 or 2013 were invited to 5-year follow-up assessments in May 2017 (n = 30). Changes in physiological outcomes over time between the football participants (FTG) and nonparticipants (CON) were examined. Twenty-two men accepted the invitation of which 11, aged 71.3 ± 3.8 years, had continued to play self-organized football 1.7 (SD 0.5) times per week for 4½ years (±8 months). At 5 years, right femoral neck bone mineral density (BMD) had improved significantly in the FTG compared to CON (P = .028). No other significant between-group differences were observed. In FTG, RHR decreased by 4.3 bpm (P = .009) with no changes in CON. Muscle mass, knee-extensor muscle strength, VO2 max, and postural balance decreased in both groups. In FTG, the fraction of training time with HR between 80%-90% or >90% of HRmax was 29.9% (SD 20.6) and 22.8% (SD 28.7), respectively. Average distance covered during 3 × 20 minutes of football training was 2524 m (SD 525). Football training over a 5-year period was associated with preserved femoral neck BMD in elderly men with PCa managed on ADT. Intensity during football training was >80% of HRmax for 51% of training time after 5 years. Body composition and physical capacity deteriorated over 5 years regardless of football participation.


Asunto(s)
Densidad Ósea , Neoplasias de la Próstata/fisiopatología , Fútbol , Anciano , Presión Sanguínea , Composición Corporal , Fémur , Estudios de Seguimiento , Frecuencia Cardíaca , Humanos , Lípidos/sangre , Masculino , Fuerza Muscular , Músculo Esquelético/fisiología , Consumo de Oxígeno , Equilibrio Postural
4.
Osteoporos Int ; 27(4): 1507-1518, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26572756

RESUMEN

UNLABELLED: Androgen deprivation therapy (ADT) for prostate cancer (PCa) impairs musculoskeletal health. We evaluated the efficacy of 32-week football training on bone mineral density (BMD) and physical functioning in men undergoing ADT for PCa. Football training improved the femoral shaft and total hip BMD and physical functioning parameters compared to control. INTRODUCTION: ADT is a mainstay in PCa management. Side effects include decreased bone and muscle strength and increased fracture rates. The purpose of the present study was to evaluate the effects of 32 weeks of football training on BMD, bone turnover markers (BTMs), body composition, and physical functioning in men with PCa undergoing ADT. METHODS: Men receiving ADT >6 months (n = 57) were randomly allocated to a football training group (FTG) (n = 29) practising 2-3 times per week for 45-60 min or to a standard care control group (CON) (n = 28) for 32 weeks. Outcomes were total hip, femoral shaft, femoral neck and lumbar spine (L2-L4) BMD and systemic BTMs (procollagen type 1 amino-terminal propeptide, osteocalcin, C-terminal telopeptide of type 1 collagen). Additionally, physical functioning (postural balance, jump height, repeated chair rise, stair climbing) was evaluated. RESULTS: Thirty-two-week follow-up measures were obtained for FTG (n = 21) and for CON (n = 20), respectively. Analysis of mean changes from baseline to 32 weeks showed significant differences between FTG and CON in right (0.015 g/cm(2)) and left (0.017 g/cm(2)) total hip and in right (0.018 g/cm(2)) and left (0.024 g/cm(2)) femoral shaft BMD, jump height (1.7 cm) and stair climbing (-0.21 s) all in favour of FTG (p < 0.05). No other significant between-group differences were observed. CONCLUSIONS: Compared to standard care, 32 weeks of football training improved BMD at clinically important femoral sites and parameters of physical functioning in men undergoing ADT for PCa.


Asunto(s)
Antagonistas de Andrógenos/efectos adversos , Antineoplásicos Hormonales/efectos adversos , Densidad Ósea/fisiología , Enfermedades Óseas Metabólicas/prevención & control , Neoplasias de la Próstata/terapia , Fútbol , Anciano , Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos Hormonales/uso terapéutico , Composición Corporal/efectos de los fármacos , Composición Corporal/fisiología , Densidad Ósea/efectos de los fármacos , Enfermedades Óseas Metabólicas/inducido químicamente , Enfermedades Óseas Metabólicas/fisiopatología , Terapia por Ejercicio/efectos adversos , Terapia por Ejercicio/métodos , Fémur/fisiopatología , Estudios de Seguimiento , Articulación de la Cadera/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Fuerza Muscular/fisiología , Músculo Esquelético/fisiopatología , Cooperación del Paciente , Aptitud Física/fisiología , Equilibrio Postural/efectos de los fármacos , Equilibrio Postural/fisiología , Neoplasias de la Próstata/fisiopatología , Terapia Recreativa/métodos
7.
Ann Oncol ; 26(4): 737-742, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25542924

RESUMEN

BACKGROUND: Screening programmes for contralateral carcinoma in situ (CIS) testis in patients with unilateral germ-cell cancer (GCC) have never been evaluated. We investigated the effect of screening for contralateral CIS in a large nation-wide, population-based study. PATIENTS AND METHODS: A contralateral single-site biopsy was offered to 4130 patients in whom GCC had been diagnosed in 1984-2007 (screened cohort); 462 patients in whom GCC was diagnosed in 1984-1988 comprised the unscreened cohort. Cases with CIS were offered radiotherapy. Initially CIS-negative biopsies in patients with metachronous GCC were revised according to today's standards. Risk for metachronous GCC was estimated using cumulative incidence and the Cox proportional hazards model. RESULTS: In the screened cohort, contralateral CIS was found in 181 (4.4%) patients. The cumulative incidence of metachronous GCC after 20 years was 1.9% in the screened cohort and 3.1% in the unscreened cohort (P = 0.097), hazard ratio (HR) for the unscreened cohort: 1.59 (P = 0.144). Expert revision with contemporary methodology of CIS-negative biopsy samples from patients with metachronous cancer revealed CIS in 17 out of 45 (38%) cases. Decreased risks for metachronous GCC were related to older age at diagnosis (HR 0.52 per 10 years, P < 0.001) and chemotherapy (HR 0.35, P = 0.002). Limitations include the small number of patients in the unscreened cohort and the retrospective study design. CONCLUSIONS: Our evaluation of a national population-based screening programme for contralateral CIS in patients with testicular cancer showed no significant difference in the risk for metachronous GCC between a screened and an unscreened cohort. Single-site biopsy including modern immunohistochemistry does not identify all cases of CIS.


Asunto(s)
Carcinoma in Situ/diagnóstico , Carcinoma in Situ/epidemiología , Detección Precoz del Cáncer , Neoplasias de Células Germinales y Embrionarias/epidemiología , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Primarias Múltiples/epidemiología , Neoplasias Testiculares/epidemiología , Adulto , Carcinoma in Situ/terapia , Estudios de Cohortes , Terapia Combinada , Dinamarca/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Estadificación de Neoplasias , Neoplasias de Células Germinales y Embrionarias/patología , Neoplasias de Células Germinales y Embrionarias/terapia , Neoplasias Primarias Múltiples/terapia , Pronóstico , Medición de Riesgo , Neoplasias Testiculares/patología , Neoplasias Testiculares/terapia
8.
Scand J Med Sci Sports ; 24 Suppl 1: 105-12, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24944134

RESUMEN

Androgen deprivation therapy (ADT) remains a cornerstone in the management of patients with prostate cancer (PCa) despite adverse effects on body composition and functional parameters. We compared the effects of football training with standard care in PCa patients managed with ADT (> 6 months). Fifty-seven men aged 67 (range: 43-74) were randomly assigned to a football group (FG, n = 29) or a usual care control group (CON, n = 28). The primary outcome was change in lean body mass (LBM) assessed by dual-energy X-ray absorptiometry scanning. Secondary outcomes included changes in knee-extensor muscle strength (one repetition maximum), fat percentage, and maximal oxygen uptake (VO2max ). Mean heart rate during training was 137.7 (standard deviation 13.7) bpm or 84.6 (3.9)% HRmax. In FG, LBM increased by 0.5 kg [95% confidence interval (CI) 0.1-0.9; P = 0.02] with no change in CON (mean group difference 0.7 kg; 95% CI 0.1-1.2; P = 0.02). Also, muscle strength increased in FG (8.9 kg; 95% CI 6.0-11.8; P < 0.001) with no change in CON (mean group difference 6.7 kg; 95% CI 2.8-10.7; P < 0.001). In FG, VO2max increased (1.0 mL/kg/min; 95% CI 0.2-1.9; P = 0.02) and fat percentage tended to decrease (0.7%; 95%CI 1.3-0.0; P = 0.06), but these changes were not significantly different from CON. In conclusion, football training over 12 weeks improved LBM and muscle strength compared with usual care in men with prostate cancer receiving ADT.


Asunto(s)
Antagonistas de Andrógenos/efectos adversos , Antineoplásicos/efectos adversos , Composición Corporal , Terapia por Ejercicio/métodos , Orquiectomía/efectos adversos , Neoplasias de la Próstata/rehabilitación , Fútbol/fisiología , Absorciometría de Fotón , Adiposidad/efectos de los fármacos , Adulto , Anciano , Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos/uso terapéutico , Composición Corporal/efectos de los fármacos , Terapia Combinada , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Humanos , Masculino , Persona de Mediana Edad , Fuerza Muscular/efectos de los fármacos , Fuerza Muscular/fisiología , Consumo de Oxígeno/efectos de los fármacos , Consumo de Oxígeno/fisiología , Aptitud Física , Neoplasias de la Próstata/terapia , Método Simple Ciego , Resultado del Tratamiento
9.
Scand J Med Sci Sports ; 24 Suppl 1: 113-21, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24944135

RESUMEN

Evidence is accumulating that exercise-based rehabilitation improves physical capacity and quality of life in cancer survivors. However, recruitment and persistence of male cancer patients in rehabilitation and physical activity are low and novel health promotion strategies are warranted. The purpose of this study was to gain an understanding of the meaning of recreational football as a team and interaction-oriented health-promoting activity in men with prostate cancer (n = 26). Qualitative data were collected through six focus group interviews (n = 4-6) and 20 h of participant observations. The two data sets were analyzed using framework analysis. The analysis produced 11 subthemes that were structured into three overarching themes: (a) motivational drivers; (b) united in sport; and (c) confirmation of own capacity. The findings indicated that participants regarded football as a welcome opportunity to regain control and acquire a sense of responsibility for own health without assuming the patient role, and football training legitimized and promoted mutual caring behavior in a male-oriented context. In conclusion, the study suggests that football, due to its cultural representation of masculine ideals, may be a potent and unique strategy for increasing recruitment and adherence to physical activity in prostate cancer patients.


Asunto(s)
Actitud Frente a la Salud , Promoción de la Salud/métodos , Relaciones Interpersonales , Motivación , Neoplasias de la Próstata/rehabilitación , Autoeficacia , Fútbol/psicología , Anciano , Grupos Focales , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Próstata/psicología , Investigación Cualitativa
10.
Br J Cancer ; 111(1): 8-16, 2014 Jul 08.
Artículo en Inglés | MEDLINE | ID: mdl-24867693

RESUMEN

BACKGROUND: Bleomycin-etoposid-cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes. METHODS: Thirty GCC patients were randomly assigned to resistance training (resistance training group (INT), n=15) or usual care (CON, n=15) during 9 weeks of BEP therapy. Resistance training consisted of thrice weekly sessions of four exercises, 3-4 sets/exercise of 10-15 repetitions at 12-15 repetition maximum load. The primary endpoint was muscle fibre size, assessed in muscle biopsies from musculus vastus lateralis. Secondary endpoints were fibre phenotype composition, body composition, strength, blood biochemistry and patient-reported endpoints. Healthy age-matched subjects (REF, n=19) performed the same RT-programme for comparison purposes. RESULTS: Muscle fibre size decreased by -322 µm(2) (95% confidence interval (CI): -899 to 255; P=0.473) in the CON-group and increased by +206 µm(2) (95% CI: -384 to 796; P=0.257) in the INT-group (adjusted mean difference (AMD), +625 µm(2), 95% CI: -253 to 1503, P=0.149). Mean differences in type II fibre size (AMD, +823 µm(2), P=0.09) and lean mass (AMD, +1.49 kg, P=0.07) in favour of the INT-group approached significance. The REF-group improved all muscular endpoints and had significantly superior changes compared with the INT-group (P<0.05). CONCLUSIONS: BEP was associated with significant reduction in lean mass and strength and trends toward unfavourable changes in muscle fibre size and phenotype composition. Resistance training was safe and attenuated dysfunction in selected endpoints, but BEP blunted several positive adaptations observed in healthy controls. Thus, our study does not support the general application of resistance training in this setting but larger-scaled trials are required to confirm this finding.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Músculo Esquelético/efectos de los fármacos , Neoplasias de Células Germinales y Embrionarias/terapia , Entrenamiento de Fuerza/efectos adversos , Entrenamiento de Fuerza/métodos , Neoplasias Testiculares/terapia , Adulto , Bleomicina/administración & dosificación , Bleomicina/efectos adversos , Cisplatino/administración & dosificación , Cisplatino/efectos adversos , Terapia Combinada , Etopósido/administración & dosificación , Etopósido/efectos adversos , Humanos , Masculino , Músculo Esquelético/fisiopatología , Neoplasias de Células Germinales y Embrionarias/tratamiento farmacológico , Neoplasias de Células Germinales y Embrionarias/fisiopatología , Estudios Prospectivos , Método Simple Ciego , Neoplasias Testiculares/tratamiento farmacológico , Neoplasias Testiculares/fisiopatología
11.
Eur J Cancer Care (Engl) ; 23(5): 653-67, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24750506

RESUMEN

Chemotherapy-related pain is a well-known side effect in cancer patient receiving chemotherapy. However, limited knowledge exists describing whether exercise exacerbates existing pain. Aim of the research was to explore muscle and joint pain experienced by women with breast cancer receiving adjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel and factor support and concurrently participating in an exercise intervention. The study used individual semi-structured interviews (pre- and post-intervention). Fifteen women were interviewed. The multimodal group intervention comprised supervised training: high-intensity cardiovascular, heavy resistance and relaxation, massage and body-awareness (9 h weekly, 6 weeks). The analysis revealed five categories: Abrupt pain - a predominant side effect, cogitated pain management, the adapted training, non-immediate exacerbation of pain and summarised into the essence of chemotherapy related muscle and joint pain in exercise breast cancer patients; exercise despite pain. Findings indicate that the patients' perception of sudden onset of chemotherapy-related muscle and joint pain was not aggravated by training. Pain intensity peaked between 2 and 9 days after chemotherapy and is described to be stabbing pain with a feeling of restlessness in the body. The patients demonstrated a high adherence rate to the exercise intervention caused by their own willpower and camaraderie of the group.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Artralgia/etiología , Neoplasias de la Mama/tratamiento farmacológico , Terapia por Ejercicio/efectos adversos , Mialgia/etiología , Manejo del Dolor/métodos , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Artralgia/terapia , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Femenino , Humanos , Entrevista Psicológica , Persona de Mediana Edad , Mialgia/terapia , Dimensión del Dolor , Cooperación del Paciente , Calidad de Vida , Encuestas y Cuestionarios
12.
Ann Oncol ; 25(5): 947-58, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24401927

RESUMEN

BACKGROUND: Muscle dysfunction is a prevalent phenomenon in the oncology setting where patients across a wide range of diagnoses are subject to impaired muscle function regardless of tumor stage and nutritional state. Here, we review the current evidence describing the degree, causes and clinical implications of muscle dysfunction in cancer patients. The efficacy of exercise training to prevent and/or mitigate cancer-related muscle dysfunction is also discussed. DESIGN: We identified 194 studies examining muscular outcomes in cancer patients by searching PubMed and EMBASE databases. RESULTS: Muscle dysfunction is evident across all stages of the cancer trajectory. The causes of cancer-related muscle dysfunction are complex, but may involve a wide range of tumor-, therapy- and/or lifestyle-related factors, depending on the clinical setting of the individual patient. The main importance of muscle dysfunction in cancer patients lies in the correlation to vital clinical end points such as cancer-specific and all-cause mortality, therapy complications and quality of life (QoL). Such associations strongly emphasize the need for effective therapeutic countermeasures to be developed and implemented in oncology practice. Significant progress has been made over the last decade in the field of exercise oncology, indicating that exercise training constitutes a potent modulator of skeletal muscle function in patients with cancer. CONCLUSION: There are clear associations between muscle dysfunction and critical clinical end points. Yet there is a discrepancy between timing of exercise intervention trials, which can improve muscle function, and study populations in whom muscle function are proven prognostic important for clinical end points. Thus, future exercise trials should in early-stage patients, be powered to evaluate clinical outcomes associated with improvements in muscle function, or be promoted in advanced stage settings, aiming to reverse cancer-related muscle dysfunction, and thus potentially improve time-to-progression, treatment toxicity and survival.


Asunto(s)
Músculo Esquelético/fisiopatología , Neoplasias/fisiopatología , Animales , Terapia por Ejercicio , Humanos , Fuerza Muscular , Músculo Esquelético/patología , Neoplasias/mortalidad , Neoplasias/terapia , Calidad de Vida , Resultado del Tratamiento
13.
Br J Cancer ; 108(10): 1994-7, 2013 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-23652308

RESUMEN

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC. METHODS: Patients with advanced ACC were included in this phase II trial investigating the response to a combination of cisplatin (50 mg m(-2)) and docetaxel (60 mg m(-2)) administered with a 3-week interval. RESULTS: Nineteen patients were included in this study. The response rate was 21% (95% CI: 3-39%). No patients obtained a complete response, 32% had stable disease, and 37% progressed while on treatment. The median progression-free survival (PFS) was 3 months (95% CI: 0.7-5.3 months) and 1 year PFS was 21% (95% CI: 3-39%). Median survival was 12.5 months (95% CI: 6-19 months). The predominant grade 3/4 toxicity was neutropenia (35%); febrile neutropenia occurred in 5% of cycles. CONCLUSION: This study could not demonstrate that the combination of cisplatin and docetaxel has higher efficacy than other regimens reported in previous studies.


Asunto(s)
Neoplasias de la Corteza Suprarrenal/tratamiento farmacológico , Carcinoma Corticosuprarrenal/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Cisplatino/administración & dosificación , Taxoides/administración & dosificación , Neoplasias de la Corteza Suprarrenal/mortalidad , Neoplasias de la Corteza Suprarrenal/patología , Carcinoma Corticosuprarrenal/mortalidad , Carcinoma Corticosuprarrenal/patología , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Cisplatino/efectos adversos , Progresión de la Enfermedad , Docetaxel , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis de Supervivencia , Taxoides/efectos adversos , Resultado del Tratamiento , Adulto Joven
14.
Ann Oncol ; 24(9): 2267-73, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23704198

RESUMEN

BACKGROUND: Sedentary behavior and impaired cardiovascular reserve capacity are common late effects of cancer therapy emphasizing the need for effective strategies to increase physical activity (PA) in cancer survivors. We examined the efficacy of a 12-month exercise-based rehabilitation program on self-reported PA, cardiorespiratory fitness (VO2peak), strength, and patient-reported outcomes. PATIENTS AND METHODS: Two hundred fourteen post-treatment cancer survivors were randomly assigned to a 12-month rehabilitation program consisting of individual (x3) and group-based (x6) counseling in combination with once weekly high-intensity group-based exercise training (the Copenhagen Physical Activity after Cancer Treatment, PACT; n = 108) or to a health evaluation program (HE, n = 106). Study outcomes were assessed at baseline, 6 months, and 12 months. RESULTS: After 12 months, the percentage of patients reporting meeting PA goal behavior (≥3 h/week) was significantly increased in the PACT group versus the HE group (70.4% versus 43.4%, P = 0.001). Repeated measures analyses indicated a statistically significant improvement in VO2peak (l min(-1)) in favour of PACT (treatment effect ratio = 1.04; 95% confidence interval 1.00-1.07; P = 0.032). Significant between group differences were also observed for strength (P < 0.001), depression (P = 0.020) and mental health (P = 0.040). CONCLUSION: A 12-month exercise-based rehabilitation program is an effective strategy to promote PA and improve VO2peak in cancer survivors.


Asunto(s)
Ejercicio Físico , Estado de Salud , Neoplasias/rehabilitación , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Actividad Motora , Aptitud Física , Calidad de Vida , Rehabilitación/métodos , Sobrevivientes , Resultado del Tratamiento
15.
Scand J Med Sci Sports ; 22(6): 804-15, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21599754

RESUMEN

Lung cancer patients experience loss of physical capacity, dyspnea, pain, reduced energy and psychological distress. The aim of this study was to explore feasibility, health benefits and barriers of exercise in former sedentary patients with advanced stage lung cancer, non-small cell lung cancer (NSCLC) (III-IV) and small cell lung cancer (SCLC) (ED), undergoing chemotherapy. The intervention consisted of a hospital-based, supervised, group exercise and relaxation program comprising resistance-, cardiovascular- and relaxation training 4 h weekly, 6 weeks, and a concurrent unsupervised home-based exercise program. An explorative study using individual semi-structured interviews (n=15) and one focus group interview (n=8) was conducted among the participants. Throughout the intervention the patients experienced increased muscle strength, improvement in wellbeing, breathlessness and energy. The group exercise and relaxation intervention showed an adherence rate of 76%, whereas the patients failed to comply with the home-based exercise. The hospital-based intervention initiated at time of diagnosis encouraged former sedentary lung cancer patients to participation and was undertaken safely by cancer patients with advanced stages of disease, during treatment. The patients experienced physical, functional and emotional benefits. This study confirmed that supervised training in peer-groups was beneficial, even in a cancer population with full-blown symptom burden and poor prognosis.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/terapia , Terapia por Ejercicio , Neoplasias Pulmonares/terapia , Terapia por Relajación , Carcinoma Pulmonar de Células Pequeñas/terapia , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/complicaciones , Carcinoma de Pulmón de Células no Pequeñas/psicología , Disnea/etiología , Disnea/terapia , Terapia por Ejercicio/psicología , Fatiga/etiología , Fatiga/terapia , Estudios de Factibilidad , Femenino , Grupos Focales , Estado de Salud , Humanos , Entrevistas como Asunto , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/psicología , Masculino , Persona de Mediana Edad , Motivación , Fuerza Muscular , Cooperación del Paciente , Terapia por Relajación/psicología , Carcinoma Pulmonar de Células Pequeñas/complicaciones , Carcinoma Pulmonar de Células Pequeñas/psicología
16.
Scand J Med Sci Sports ; 21(3): 369-77, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20136754

RESUMEN

Fatigue is frequent in cancer patients undergoing chemotherapy. Erythropoietins (EPO) have shown well-documented effects on these patients, and administered in pharmacological doses, may reduce the need for transfusion of blood cells and improve quality of life (QoL). An explorative, descriptive, non-randomised intervention study using semi-structured interviews was conducted with the aim to gain an insight into the effects and experiences associated with EPO treatment in combination with a structured 6-week physical exercise intervention. Sixteen cancer patients with evidence of disease, who had received at least one cycle chemotherapy, participated. Participants received 500 µg Darbepoetin Alfa (DA) every 3 weeks during the intervention. Four typologies of patients were identified with regard to DA effects. The interviews revealed that eleven patients experienced some kind of immediate improvement in cognitive and emotional functioning, and subjective daily well-being. Furthermore physical improvement and changes in QoL outcomes showed no significant differences between the study group and a reference group. A significant increase in the hemoglobin concentration (7.14-7.87 mmol/L, P<0.05) was found in the study group. The future use of EPO in cancer patients is hampered by the reported negative influence of EPO on the prognosis in some diagnoses and should be based on randomized studies.


Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Eritropoyetina/análogos & derivados , Terapia por Ejercicio , Fatiga/tratamiento farmacológico , Hematínicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Adolescente , Adulto , Anciano , Darbepoetina alfa , Eritropoyetina/uso terapéutico , Fatiga/etiología , Fatiga/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/complicaciones , Resultado del Tratamiento , Adulto Joven
17.
Scand J Med Sci Sports ; 19(1): 55-66, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18266788

RESUMEN

Cancer and treatment can negatively affect the body's performance and appearance. Exercise has been tested in a few studies for altered body image among middle-aged women with breast cancer. The aim of the study was to explore how young pre-cancer athletes of both genders experience disease- and treatment-related physical fitness and appearance changes while undergoing chemotherapy and participating in a 6-week group exercise intervention. A prospective, explorative study using semi-structured interviews was conducted before and at termination of the intervention. The study included 22 cancer patients (median age 28 years). The young athletes experienced a change from a high level of physical activity, body satisfaction and a positive self-identity to a low level of physical activity, body denial and a negative self-identity. In the program, the patients experienced increased physical strength and recapture of certain aspects of their former positive body perception. Deterioation of muscle functions caused by chemotherapy was particularly painful to these patients, independent of gender and age. Young physically active patients are heavily dependent on their physical capacity, body satisfaction and self-identity. This should be taken into account when designing programs to rehabilitate and encourage these patients through the often-strenuous antineoplastic treatments.


Asunto(s)
Ejercicio Físico/fisiología , Neoplasias/tratamiento farmacológico , Desempeño Psicomotor/fisiología , Deportes , Sobrevivientes , Adolescente , Adulto , Imagen Corporal , Dinamarca , Femenino , Procesos de Grupo , Humanos , Entrevistas como Asunto , Masculino , Fuerza Muscular , Neoplasias/rehabilitación , Estudios Prospectivos , Adulto Joven
18.
Brain ; 130(Pt 4): 1076-88, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17301082

RESUMEN

Although it is well known that cisplatin causes a sensory neuropathy, the primary site of involvement is not established. The clinical symptoms localized in a stocking-glove distribution may be explained by a length dependent neuronopathy or by a distal axonopathy. To study whether the whole neuron or the distal axon was primarily affected, we have carried out serial clinical and electrophysiological studies in 16 males with testicular cancer before or early and late during and after treatment with cisplatin, etoposide and bleomycin at limited (<400 mg/m2 cisplatin), conventional (approximately 400 mg/m2 cisplatin) or high (>400 mg/m2 cisplatin) doses. At cumulative doses of cisplatin higher than 300 mg/m2 the patients lost distal tendon and H-reflexes and displayed reduced vibration sense in the feet and the fingers. The amplitudes of sensory nerve action potentials (SNAP) from the fingers innervated by the median nerve and the dorsolateral side of the foot innervated by the sural nerve were 50-60% reduced, whereas no definite changes occurred at lower doses. The SNAP conduction velocities were reduced by 10-15% at cumulative doses of 400-700 mg/m2 consistent with loss of large myelinated fibres. SNAPs from primarily Pacinian corpuscles in digit 3 and the dorsolateral side of the foot evoked by a tactile probe showed similar changes to those observed in SNAPs evoked by electrical stimulation. At these doses, somatosensory evoked potentials (SEPs) from the tibial nerve had increased latencies of peripheral, spinal and central responses suggesting loss of central processes of large dorsal root ganglion cells. Motor conduction studies, autonomic function and warm and cold temperature sensation remained unchanged at all doses of cisplatin treatment. The results of these studies are consistent with degeneration of large sensory neurons whereas there was no evidence of distal axonal degeneration even at the lowest toxic doses of cisplatin.


Asunto(s)
Antineoplásicos/efectos adversos , Carcinoma Embrionario/tratamiento farmacológico , Cisplatino/efectos adversos , Neuronas Aferentes/efectos de los fármacos , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Neoplasias Testiculares/tratamiento farmacológico , Potenciales de Acción/fisiología , Adulto , Bleomicina/efectos adversos , Carcinoma Embrionario/fisiopatología , Etopósido/efectos adversos , Potenciales Evocados Somatosensoriales/fisiología , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Conducción Nerviosa/fisiología , Neuronas Aferentes/fisiología , Enfermedades del Sistema Nervioso Periférico/fisiopatología , Estudios Prospectivos , Reflejo/fisiología , Seminoma/tratamiento farmacológico , Seminoma/fisiopatología , Trastornos de la Sensación/inducido químicamente , Trastornos de la Sensación/fisiopatología , Umbral Sensorial/fisiología , Neoplasias Testiculares/complicaciones , Tacto/fisiología
19.
Scand J Med Sci Sports ; 16(6): 403-11, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17121642

RESUMEN

BACKGROUND: Over the past few years there has been a growing interest in the field of physical exercise in rehabilitation of cancer patients, leading to requirements for objective maximum physical capacity measurement (maximum oxygen uptake (VO(2max)) and one-repetition maximum (1RM)) to determine dose-response levels in different cancer diagnoses. AIM: To explore the patients' experiences of maximum physical capacity testing while concurrently undergoing chemotherapy and participating in a 6-week, 9 h weekly multidimensional exercise program. DESIGN AND METHOD: Prospective, exploratory study using semi-structured qualitative interviews conducted prior to and at termination of the program. The study included 100 patients (18-65 years, median 42 years) with or without residual disease and with mixed diagnoses. RESULTS: Following the intervention, cancer patients felt significantly safer in performing maximum physical capacity tests as these motivated them through self-perceived competitiveness and set a standard that served to encourage peak performance. CONCLUSION: The positive attitudes in this sample towards maximum physical capacity open the possibility of introducing physical testing early in the treatment process. However, the patients were self-referred and thus highly motivated and as such are not necessarily representative of the whole population of cancer patients treated with chemotherapy.


Asunto(s)
Tolerancia al Ejercicio , Ejercicio Físico , Neoplasias/rehabilitación , Adolescente , Adulto , Anciano , Antineoplásicos/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Motivación , Fuerza Muscular , Neoplasias/tratamiento farmacológico , Neoplasias/psicología , Consumo de Oxígeno , Estudios Prospectivos
20.
Scand J Med Sci Sports ; 16(5): 349-57, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16978255

RESUMEN

The purpose of the study was to examine the effects of a supervised high- and low-intensity structured training program in cancer patients concurrently undergoing chemotherapy. Seventy patients, in different stages of the disease and with different diagnoses (48 females, 22 males), between 18 and 65 years of age (mean age 42.8) participated in a 9-h weekly training program over 6 weeks. The intervention involved physical exercise, relaxation, massage, and body-awareness training. Physical capacity (one-repetition maximum tests (1RM), VO2max) and body composition (weight, skin-fold) were compared before and after the exercise intervention. The average increase in muscular strength was 41.3% (P<0.001) and 14.5% in aerobic fitness (pre: 2.27+/-0.597 L/min, post: 2.56+/-0.644 L/min, (P<0.001). The exercise intervention significantly increased the weight of the subjects by 1% (pre: 72.62+/-13.42 kg, post: 73.25+/-13.44 kg, P=0.016). There was a significant decrease in skin-fold measurements by 3% (P=0.031). The exercise intervention was well tolerated, provided that daily screening criteria were adhered to. The effects of resistance and cardiovascular training observed in this short-term study support the theory that exercise is a beneficial intervention strategy for increasing muscle strength and aerobic fitness during antineoplastic chemotherapy. This type of exercise program can be an important component of complementary treatment for cancer patients undergoing chemotherapy.


Asunto(s)
Terapia por Ejercicio/métodos , Tolerancia al Ejercicio/fisiología , Neoplasias/tratamiento farmacológico , Neoplasias/fisiopatología , Adolescente , Adulto , Anciano , Antineoplásicos/uso terapéutico , Peso Corporal , Fenómenos Fisiológicos Cardiovasculares , Terapia por Ejercicio/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fenómenos Fisiológicos Musculoesqueléticos , Aptitud Física , Grosor de los Pliegues Cutáneos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...